Tags : DNA-PK Inhibitors


Vertex Signs an Exclusive License Agreement with Merck KGaA for

Shots: Merck KGaA to receive upfront, milestones, and royalties on net sales. Vertex to get exclusive license rights for Merck’s two DNA-dependent protein kinase (DNA-PK) inhibitors, M9831 (formerly known as VX-984) and a preclinical candidate for six genetic disease indications to fields of gene-editing Vertex will have an option to add indications to the above […]Read More